How do GLP-1 drugs actually change the way people eat?
GLP-1 receptor agonists (like semaglutide, tirzepatide) don't just suppress appetite through a simple 'fullness' signal. A 2025 survey of 101 patients found that after starting the drug, people reported being significantly more aware of their true hunger cues and much less likely to eat past the point of fullness [4]. More strikingly, they reported a sharp drop in the urge to eat in response to external triggers—like seeing food ads, smelling food, or feeling stressed or sad [4]. This suggests the drugs rewire the brain's reward response to food, making emotional and environmental cues less powerful than the body's actual need for fuel.
This behavioral shift is backed by a massive 2025 study of 215,970 diabetes patients that mapped GLP-1 effects across 175 health outcomes [2]. Compared to usual diabetes care, GLP-1 users had lower rates of substance use disorders and psychotic disorders—hinting that the drug may dampen cravings beyond just food [2]. Together, these two studies [2][4] converge on the same conclusion from different angles: GLP-1s change eating behavior by reducing the brain's sensitivity to external and emotional triggers, not just by slowing stomach emptying.
Could these behavior changes actually shift public health—and what are the trade-offs?
If 30 million Americans are projected to be consistent GLP-1 users by 2030 [5], even modest per-person changes in eating behavior could have population-level effects. A 2026 analysis estimated that widespread GLP-1 use could reduce greenhouse gas emissions by up to 760 kg of CO2 per person per year—more than switching to an electric vehicle or adopting a vegetarian diet—simply because people eat less food, requiring less production and transport [5]. That's a public health benefit that extends beyond individual weight loss to the environment.
But the same large 2025 study that found reduced addiction and dementia risks also found clear downsides: GLP-1 users had higher rates of gastrointestinal disorders, hypotension (low blood pressure), fainting, arthritis, kidney stones, and drug-induced pancreatitis [2]. A separate 2022 study of over 2,500 thyroid cancer cases found that using GLP-1s for 1-3 years was linked to a 58% higher risk of all thyroid cancer and a 78% higher risk of medullary thyroid cancer [3]. These risks are not trivial. The net public health impact will depend on how well doctors screen for these risks and whether the behavioral benefits (less obesity, less addiction, less food waste) outweigh the harms (pancreatitis, thyroid cancer, kidney problems).
Importantly, the evidence is mixed on pregnancy safety. A 2023 study of over 3.5 million pregnancies found that GLP-1 use during early pregnancy was not associated with a large increased risk of birth defects compared to insulin, but the numbers were small and the estimates imprecise [1]. This means the behavioral changes that help adults lose weight could pose unknown risks if used in pregnant women, limiting the drug's public health reach.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2026, 3 from 2024 or later, 3 in Q1 journals, collectively cited 572 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 53 papers retrieved from a database of over 500 million.
Sources used in this answer
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy
In a cohort study of over 3.5 million pregnancies across four countries, GLP-1 use in early pregnancy was not linked to a large increased risk of major birth defects compared to insulin, but estimates were imprecise due to small numbers.
Mapping the effectiveness and risks of GLP-1 receptor agonists
In the largest study here (215,970 GLP-1 users), GLP-1 use was associated with reduced risk of substance use disorders, seizures, and dementia, but increased risk of gastrointestinal disorders, pancreatitis, kidney stones, and hypotension.
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
In a nested case-control study of 2,562 thyroid cancer cases, GLP-1 use for 1-3 years was associated with a 58% higher risk of all thyroid cancer and a 78% higher risk of medullary thyroid cancer.
Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
A survey of 101 patients found that after starting GLP-1s, participants reported significantly less eating in response to emotional, sensory, and situational cues, and greater awareness of hunger and fullness.
Beyond Public Health and Medicine: The Potential Impact of GLP-1s and Other Incretin Mimetic Medications on Greenhouse Gas Emissions.
A speculative life-cycle analysis estimated that widespread GLP-1 use could reduce greenhouse gas emissions by up to 760 kg CO2 per person per year, more than switching to an electric vehicle or vegetarian diet.